Document is current
Any future updates will be listed below
-
Authors
Lee, Robin D. https://orcid.org/0000-0003-2998-8131
Knutson, Todd P. https://orcid.org/0000-0001-8431-9964
Munro, Sarah A.
Miller, Jeffrey T.
Heltemes-Harris, Lynn M.
Mullighan, Charles G. https://orcid.org/0000-0002-1871-1850
Jepsen, Kristen
Farrar, Michael A. https://orcid.org/0000-0002-5569-0366
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI124512, R01AI147540)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01CA232317, P30CA077598, F30CA232399, R35CA197695, CA021765)
U.S. Department of Health & Human Services | National Institutes of Health (T32 GM008244)
- License Information
-
More Information
Article History
Received: 21 January 2022
Accepted: 16 September 2022
First Online: 31 October 2022
Competing interests
: C.G.M. provides consultation and advise for Illumina (compensated), Faze Medicines (compensated) and Beam Therapeutics (compensated) and receives research funding from Pfizer and Abbvie. The remaining authors declare no competing interests.
